Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

Finding a clue to the origin of treatment-resistant leukemia in kids

3.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

4.

Have the Harms of Lung Cancer Screening Been Exaggerated?

5.

Study suggests exercise could reduce breast cancer recurrence


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot